Program
zelicapavir
Also written as “EDP-938”, “zelicapavir (therapeutic dose)” and “zelicapavir (supratherapeutic dose)”.
Its studies are mostly in Respiratory Syncytial Virus Infections · Pulmonary Disease, Chronic Obstructive, led by Enanta Pharmaceuticals.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Enanta Pharmaceuticals | 142 open or running | phase 3since Oct 26, 2026 | Dec 20, 2017 | Dec 2026phase 2 · NCT07482657 |
Also a collaborator on its studies: ppd-development-lp and hvivo-services-limited.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 20, 2017First study: phase 1 study in Respiratory Syncytial Virus InfectionsFirst studyNCT03384823 · 90 enrolled · United States
- Sep 28, 2018Phase 2 study in Respiratory Syncytial Virus InfectionsNCT03691623 · 179 enrolled · United Kingdom
- Nov 8, 20182 phase 1 studies in Respiratory Syncytial Virus InfectionsNCT03750383, NCT03755778
- Dec 3, 2019Phase 2 study in Respiratory Syncytial VirusNCT04196101 · 82 enrolled · United States, Argentina, Bulgaria and more
- Jul 30, 2020Phase 1 study in Respiratory Syncytial Virus InfectionsNCT04498741 · 89 enrolled · United States
- Nov 11, 2020Phase 2 study in Respiratory Syncytial Virus InfectionsNCT04633187 · 9 enrolled · United States, Argentina, Belgium and more
- Mar 23, 2021Phase 2 study in Respiratory Syncytial Virus (RSV)NCT04816721 · 99 enrolled · United States, Argentina, Australia and more
- Apr 29, 2021Phase 1 study in Respiratory Syncytial Virus InfectionsNCT04871724 · 24 enrolled · United States
- Jun 9, 2021Phase 1 study in Respiratory Syncytial Virus (RSV)NCT04927793 · 8 enrolled · United States
- Oct 3, 2022Phase 2 study in Respiratory Syncytial Virus InfectionsNCT05568706 · 187 enrolled · United States, Argentina, Bulgaria and more
- Aug 27, 2024Phase 1 study in Respiratory Syncytial Virus InfectionsNCT06601192 · 72 enrolled · United States
- Mar 16, 2026Phase 2 study in Respiratory Syncytial Virus InfectionsNCT07482657 · 150 planned · Thailand
- Oct 26, 2026Phase 3 study in Pulmonary Disease, Chronic ObstructivePhase 3 reachedNCT07908381 · 860 planned · United States
Ahead
- Dec 2026Primary completion: phase 2 study in Respiratory Syncytial Virus InfectionsNCT07482657
- Jul 2029Primary completion: phase 3 study in Pulmonary Disease, Chronic ObstructiveNCT07908381
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 14 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07908381Pulmonary Disease, Chronic Obstructive · United States | 3 | Recruiting | Jul 2029 | 860 |
| NCT07482657Respiratory Syncytial Virus Infections · Thailand | 2 | Recruiting | Dec 2026 | 150 |
| NCT06601192Respiratory Syncytial Virus Infections · United States | 1 | Completed | Feb 2, 2025 | 72 |
| NCT05568706Respiratory Syncytial Virus Infections · United States, Argentina, Bulgaria and more | 2 | Completed | Jun 23, 2025 | 187 |
| NCT04927793Respiratory Syncytial Virus (RSV) · United States | 1 | Completed | Jul 4, 2021 | 8 |
| NCT04871724Respiratory Syncytial Virus Infections · United States | 1 | Completed | Mar 30, 2021 | 24 |
| NCT04816721Respiratory Syncytial Virus (RSV) · United States, Argentina, Australia and more | 2 | Completed | Aug 19, 2024 | 99 |
| NCT04633187Respiratory Syncytial Virus Infections · United States, Argentina, Belgium and more | 2 | Terminated | May 31, 2023 | 9 |
| NCT04498741Respiratory Syncytial Virus Infections · United States | 1 | Completed | May 27, 2021 | 89 |
| NCT04196101Respiratory Syncytial Virus · United States, Argentina, Bulgaria and more | 2 | Completed | Jan 4, 2022 | 82 |
| NCT03755778Respiratory Syncytial Virus Infections · United States | 1 | Completed | Jan 21, 2019 | 72 |
| NCT03750383Respiratory Syncytial Virus Infections · United States | 1 | Completed | Nov 17, 2018 | 48 |
| NCT03691623Respiratory Syncytial Virus Infections · United Kingdom | 2 | Completed | Sep 30, 2019 | 179 |
| NCT03384823Respiratory Syncytial Virus Infections · United States | 1 | Completed | Jul 3, 2018 | 90 |
How it is read
Names in the registry
- “EDP-938”, 16 entries
- “zelicapavir”, 2 entries
- “zelicapavir (therapeutic dose)”, 1 entry
- “zelicapavir (supratherapeutic dose)”, 1 entry
- “EDP-938 Dose 1”, 1 entry
Conditions, from the studies’ own filings
- Respiratory Syncytial Virus Infections, 10 studies
- Pulmonary Disease, Chronic Obstructive, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.